Greater Paris Metropolitan Region
French-American serial entrepreneur. Twenty years building healthcare startups. Five companies co-founded, three as CEO. MDR CE marking, €50M raised, 100 patients in pivotal clinical trials, Lancet and Circulation publications. €250M+ of VC, capital investment and M&A operations earlier in my career. My past roles as CEO, Chairman, and Board Member reflect my unwavering commitment to advancing medical technology and transforming innovative ideas into reality. I'm currently acting CEO of Braincoder, a class III brain implant project for profound deafness (formal incorporation October 2026, Béatrice Denys Prize 2025). I open 2 to 3 days a week to advise medtech and deeptech CEOs through their hardest calls — Seed and Series A/B preparation, MDR/FDA strategy, EU market entry, industrial scale-up, due diligence for VCs. Two packaged offers: → CEO Advisor. Sparring partner mandate, 6–12 months, 1–2 days a month. For CEOs who want an experienced peer next to them — not a passive advisor. → Strategic Missions. Scoped engagements, 2–8 weeks, on five scopes: fundraising preparation, clinical/regulatory strategy, EU market entry for US/Asia medtech, VC due diligence, business plan. Who I work with: · Founders and CEOs of French deeptech/medtech startups post-funding, structuring for the next stage. · CEOs looking for a stable sparring partner, not an occasional advisor. · US and Asia medtech companies entering the EU market. · VC funds needing external expertise on specific deals. What I bring: A CEO who has done it — CE marking, Series A/B, team structuring, board management, regulatory negotiation with ANSM, BfArM, FDA. A medtech/VC/KOL network that activates. Contractual availability, not a "let's see". Based in Paris. EU & US travel. French and English. Independent — no active non-compete clause from previous assignments. → To discuss an engagement: [email protected]
CEO Advisor and Strategic Missions for founders and CEOs of medtech/deeptech startups. Two packaged offers: - CEO Advisor — Sparring partner mandate, 6–12 months, 1–2 days/month. For CEOs who want an experienced peer next to them, not a passive advisor. - Strategic Missions — Scoped 2–8 weeks engagements on: Seed, Series A/B preparation, clinical/regulatory strategy (MDR/FDA), EU market entry for US/Asia medtech, VC due diligence, business plan. Focus sectors: ultrasound therapy, neurotech, cardiology, implantable devices, surgical robotics, SaMD/AI diagnostics, biotech & advanced therapies. EU travel. French and English.
The Braincoder project aims to develop a highly innovative new medical device designed to restore auditory perception in people with profound deafness (50 million people worldwide, including 100,000 with no therapeutic solution), without information loss, unlike current devices (cochlear implants or auditory brainstem implants). The project originates from the work of Brice Bathellier, Research Director at the Institut de l’Audition / Institut Pasteur, within a joint CNRS/INSERM research unit. The medical device is a brain implant based on artificial intelligence technology capable of translating sounds into electrical signals and directly stimulating the auditory cortex. Our implant converts sound information into the language of the brain. In June 2025, the project was awarded the Béatrice Denys Prize for its strong scientific, clinical, and entrepreneurial potential. The project is also supported by the Brain Institute (ICM) through its Neural program. The creation of a startup is planned by the end of 2026.
The National Center for Scientific Research, or CNRS, is a public organization under the responsibility of the French Ministry of Education and Research, a major player in every field of research. €4 billion budget. 33,000 employees, including 28,000 scientists. 1,100 research laboratories in France and abroad. As Board member, representative of the business community, mostly interact with the CNRS Innovation Office (DGDI) which pursues the policy for transferring research results and technologies. Key achievements: • Participated to startup programs: pre-maturation, RISE startup program, jury member for selection, mentoring. • Developed relationships with industrial players. • Participated to the external independent audit of the CNRS’s by an international commission.
Medtech company manufacturing CE-marked Valvosoft, a non-invasive, real-time image-guided medical device (class IIb in Europe, class III in US) for aortic stenosis treatment using a disruptive Ultrasound Therapy technology. • Co-founder, CEO & Chairman of the Board (2014–2023), then Board member & Development Director (2023–2025) • Built and led the company from concept to CE-marked product — non-invasive, real-time image-guided medical device (class IIb EU / class III US) for severe aortic stenosis treatment, using a disruptive ultrasound therapy technology. Defined the strategy and objectives. Oversaw, structured and financed the organization and the complete operations (Finance, HR, Legal, R&D, Preclinical, Clinical, Regulatory, Manufacturing, Communication, Marketing & Sales). Key achievements: • Raised €40 million+. • Built and managed and an international cross-functional team of 30 FTE, Recruited C-Level managers • Led tech transfer from CNRS labs Physics for Medicine and Langevin Institute. 7 patent families filed. • Defined the clinical and regulatory strategy. Led discussions with regulatory agencies in Europe (ANSM, BfArM) and US (FDA). • Built scientific advisory board and international KOL networks. • Designed and successfully ran clinical trials in Europe for CE-marking: 100 patients, 4 countries, 12 sites. Published in The Lancet and Circulation. • Obtained ISO 13485 certification under new MDR. • Set up initial manufacturing supply chain. • Served as public speaker in many international congresses, round tables and events. • Served as active member of Life Science Clusters: MEDICEN as Medtech startups Representative, of French Healthcare Association SNITEM's Ultrasound therapy Group. • Awards: Galien MedStart’Up, MedTech Innovator, SME Instrument, French Tech Health20, I-Nov...
Public-Private research consortium STOP-AS (Search Treatment and improve Outcome for Patients with Aortic Stenosis) is a research project, laureate of the second call for proposals “University Hospital Research in health” (RHU). Coordinated by Professor Hélène Eltchaninoff, head of Rouen University Hospital Cardiology Department, this project including 15 partners (11 academic partners and 4 companies) aimed to improve the knowledge on aortic stenosis and develop new therapeutics. €21 million budget. Key achievements: Pre-clinical and clinical studies, multicentre trials and national registries as well as innovative approaches to imaging, biomarkers and non-invasive ultrasound-based treatments have been implemented.